Indivior PLC (NASDAQ:INDV - Get Free Report) rose 4.7% during mid-day trading on Tuesday . The company traded as high as $9.95 and last traded at $9.99. Approximately 376,723 shares were traded during trading, a decline of 65% from the average daily volume of 1,087,194 shares. The stock had previously closed at $9.54.
Wall Street Analyst Weigh In
INDV has been the topic of a number of research reports. Piper Sandler reissued an "overweight" rating and set a $16.00 price target (up previously from $15.00) on shares of Indivior in a report on Friday, October 25th. RODMAN&RENSHAW raised Indivior to a "strong-buy" rating in a report on Tuesday, January 28th. Finally, Rodman & Renshaw initiated coverage on Indivior in a report on Tuesday, January 28th. They set a "buy" rating and a $16.00 price target on the stock.
View Our Latest Stock Report on Indivior
Indivior Trading Down 2.5 %
The stock has a fifty day simple moving average of $11.63 and a two-hundred day simple moving average of $10.95. The company has a market cap of $1.36 billion, a PE ratio of -245.69 and a beta of 0.73.
Institutional Investors Weigh In On Indivior
Institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Indivior in the 4th quarter valued at approximately $56,000. Stifel Financial Corp acquired a new stake in shares of Indivior during the 3rd quarter valued at approximately $100,000. Melqart Asset Management UK Ltd acquired a new stake in shares of Indivior during the 3rd quarter valued at approximately $132,000. Jane Street Group LLC acquired a new stake in shares of Indivior during the 3rd quarter valued at approximately $180,000. Finally, Rathbones Group PLC lifted its position in shares of Indivior by 11.6% during the 4th quarter. Rathbones Group PLC now owns 14,284 shares of the company's stock valued at $183,000 after acquiring an additional 1,483 shares during the period. Hedge funds and other institutional investors own 60.33% of the company's stock.
About Indivior
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Further Reading
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
